2 型糖尿病患者由双时相人胰岛素30 改为双时相门冬胰岛素30 治疗后血糖控制和安全性获得改善 来自A1chieve 研究的报告结果.pdfVIP

23030 A chieve 1 Nabil K. El NaggarPradana Soewondo Mohammad E. Khamseh Jian-Wen ChenJihad Haddad 983408-413. D I A B E T E S R E S E A R C H A N D C L I N I C A L P R A C T I C E 9 8 ( 2 0 1 2 ) 4 0 8 – 4 1 3 内容刊载在Sciverse ScienceDirect Diabetes Research and Clinical Practice 杂志网站主页：/locate/diabres 23030 A chieve 1 b c Nabil K. El Naggar Pradana Soewondo Mohammad E. Khamseh d e J ian-Wen Chen J ihad Haddad a Hai Al J ameaJ eddah, J eddah 21433, The Kingdom of Saudi Arabia b J alan Diponegoro No. 71, J akarta 10430, Indonesia c Firouzgar d Novo Nordisk International Operations A/S e Hamazeh 文稿信息 摘要 目的：A 1 ch i ev e® 6 3 2 32 2012829 30 BHI30 OGLD30 BIAsp30OGLD 2012920 ® 2012924 方法：A chieve 24 1 2BIAsp30 结果：B H I 30 SD 0 . 5 6 0 .2 5 IU/ k g B IA sp 30 0.57 0.25U/kg 240.62 0.28U/kg BHI30BIAsp30 HbA1c9.1% [76 mmol/mol]1.7% [18 mmol/mol] 1.6) p0.001FPGPPG p0.00124 //0.690.03 5.312.04 关键词： 0.1% 0.1 3.3kg 30 结论：2BHI30BIAsp30 BIAsp30 2 C NC 前言